Login to Your Account

Phase III in Second Half of 2014

Dopamine Road: Civitas’ $38M to Fill in Parkinson’s ‘Potholes’

By Randy Osborne
Staff Writer

Thursday, September 12, 2013
With $38 million in Series B money, Civitas Therapeutics Inc.’s can finish its ongoing, 80-patient Phase IIb trial testing inhaled levodopa (L-dopa) in Parkinson’s disease patients, and get ready for a Phase III trial that would begin in the second half of next year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription